These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30209896)

  • 21. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.
    Hagberg KW; Divan HA; Persson R; Nickel JC; Jick SS
    BMJ; 2016 Sep; 354():i4823. PubMed ID: 27659058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia.
    Di Loreto C; La Marra F; Mazzon G; Belgrano E; Trombetta C; Cauci S
    PLoS One; 2014; 9(6):e100237. PubMed ID: 24959691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review.
    Trost L; Saitz TR; Hellstrom WJ
    Sex Med Rev; 2013 May; 1(1):24-41. PubMed ID: 27784557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comorbid LUTS and erectile dysfunction: optimizing their management.
    Kaminetsky J
    Curr Med Res Opin; 2006 Dec; 22(12):2497-506. PubMed ID: 17265598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finasteride Topical Delivery Systems for Androgenetic Alopecia.
    Khan MZU; Khan SA; Ubaid M; Shah A; Kousar R; Murtaza G
    Curr Drug Deliv; 2018; 15(8):1100-1111. PubMed ID: 29366416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-finasteride syndrome: An emerging clinical problem.
    Diviccaro S; Melcangi RC; Giatti S
    Neurobiol Stress; 2020 May; 12():100209. PubMed ID: 32435662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-finasteride syndrome: a surmountable challenge for clinicians.
    Traish AM
    Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
    Said MA; Mehta A
    Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-finasteride syndrome - does it really exist?
    Maksym RB; Kajdy A; Rabijewski M
    Aging Male; 2019 Dec; 22(4):250-259. PubMed ID: 30651009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5α-Reductase inhibitors in androgenetic alopecia.
    Yim E; Nole KL; Tosti A
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.
    Gur S; Kadowitz PJ; Hellstrom WJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):81-90. PubMed ID: 23173718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review.
    Mella JM; Perret MC; Manzotti M; Catalano HN; Guyatt G
    Arch Dermatol; 2010 Oct; 146(10):1141-50. PubMed ID: 20956649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss).
    Shapiro J; Kaufman KD
    J Investig Dermatol Symp Proc; 2003 Jun; 8(1):20-3. PubMed ID: 12894990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients.
    Li X; Guo Y; Lu Y; Li H; Yan S; Li H; Li Y
    Transl Androl Urol; 2022 Oct; 11(10):1452-1457. PubMed ID: 36386264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
    Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
    Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
    Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia.
    Irwig MS
    Curr Opin Endocrinol Diabetes Obes; 2015 Jun; 22(3):248-53. PubMed ID: 25871957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring rat corpus cavernosum alterations induced by finasteride treatment and withdrawal.
    Diviccaro S; Herian M; Cioffi L; Audano M; Mitro N; Caruso D; Giatti S; Melcangi RC
    Andrology; 2024 Mar; 12(3):674-681. PubMed ID: 37621185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.